advancing connected caretm · logistics providers •expediting logistics to meet customer needs...

ADVANCING CONNECTED CARETM

May 1, 2020

Second Quarter 2020 Financial Results

This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation ReformAct of 1995. All statements included herein that are not historical facts are forward-looking statements, includingwithout limitation statements regarding Hillrom’s ability to drive sustainable profitable growth and shareholder value,the timing and success of new product launches and portfolio expansion, the achievement of long-range financialobjectives, the continuation of stable customer demand trends, a stable U.S. capital environment, the timing andsuccess of M&A and business optimization initiatives, our ability to reduce debt, implementation of our ITtransformation, the impact of tariffs, any change to the one-time impact from U.S. tax reform legislation, and all otherstatements concerning future strategy, plans, objectives, projections, expectations and intentions. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the eventsuch risks or uncertainties materialize, Hillrom’s results could be materially adversely affected. Hillrom’s actual resultsalso could be materially adversely impacted by the length and severity of the recent coronavirus pandemic(“COVID-19,” “the pandemic,” or “the virus”) and related impacts on our business, results of operations, financialcondition and prospects. For a more in-depth discussion of factors that could cause actual results to differ from thosecontained in forward-looking statements, see the discussions under the heading “Risk Factors” in the company'spreviously filed most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Except asrequired by applicable law or regulations Hillrom assumes no obligation to update or revise any forward-lookingstatements.

Certain financial figures presented herein have been presented on an adjusted basis (non-GAAP). Reconciliationbetween non-GAAP financial measures and reported GAAP financial measures are included in the appendices tothis slide deck.

Hillrom’s results contained herein reflect the new revenue recognition accounting standard, ASC 606, which Hillromadopted on a modified retrospective basis beginning in the fiscal first quarter 2019. All comparisons contained hereinwill include the new standard for the current and prior year periods.

© 2020 Hill-Rom Services, Inc. ALL RIGHTS RESERVED.

Forward Looking Statements And Non-GAAP Financial Measures

2

3


COVID-19 Response

Q2 2020 Highlights

Q2 2020 Financial Summary

Revenue Schedules

Appendix

1

2

3

4

5

Table Of Contents

4

COVID-19 Response


Our Mission Has Never Been More Vital

5

“During this unprecedented

and challenging period,

Hillrom’s mission of enhancing

outcomes for patients and

caregivers has never been

more vital. I am extremely

proud of the entire Hillrom

organization, their dedication,

and extraordinary contributions

team members are making to

support our customers as we

fight this pandemic.”

John Groetelaars,

President and CEO

Enhancing Outcomes For Patients And Their Caregivers


Playing A Pivotal Role In The Global Response

6

Ensuring

Business

Continuity

Pivoting

New Product

Innovation

Increasing

Capacity Of

Critical Products

Supporting

Frontline

Workers

HILLROM’S COVID-19 ACTIONS


Supporting Frontline Workers

7

Donating ~$6M to hospitals and charities

• Supporting communities by donating critical products to 25 U.S.

hospitals for critical and intensive care units’ fight against COVID-19

• Supporting American Nurses Foundation with $50K cash donation

and Chinese Red Cross with $2M in vital signs monitors

Mobilizing to respond in Crema, Italy

• Partnering Hillrom’s field sales and service teams with hospitals

on the front lines around the world

• Rapidly installing patient monitoring equipment for a field

hospital in Crema, Italy

Supporting response at The Mount Sinai Hospital, New York

• Expediting production and deliveries to critical hospitals, like The

Mount Sinai Hospital in New York City

• Delivering and installing new beds to help clinicians treat the surge

in COVID-19 patients


Introducing New Product Innovations

8

Pivoting R&D Efforts To Meet COVID-19 Treatment Challenges

Adapting the MetaNeb®

System to reduce cross contamination

Enhancing Connex® Spot Vital Signs Monitor to digitally capture

episodic respiratory rate

Adding remote monitoring and simplified connectivity to Welch Allyn® Spot® 4400

Vital Signs devices

Launching Voalte Extend™, a mobile communication solution for alternate sites of care

Partnering with AgileMD to provide COVID-19 clinical

pathways digitally

Utilizing patient-positioning equipment to offer prone positioning for ventilated and

non-ventilated patients

2x Smart Beds2x Thermometry2x Vital Monitoring Devices

Supporting patients with mild

to moderate respiratory

distress across acute care

settings

9


Increasing Capacity Of Critical Products

5x Non-InvasiveVentilators

Supporting COVID-19 Response With Increased Supply Of Critical Care Products

Prioritizing manufacturing to

meet increased global demand within the ICU and med-surg

units

Meeting high demand for

diagnosis and treatment of

patients where and when healthcare providers need it

Providing caregivers with the

ability to take quick and accurate vital signs measurement

amid a surge in patients

Life2000®

Non-Invasive Ventilator

SureTemp®

& CareTemp™

Progressa® ICU, Centrella® Smart+, Hillrom® 900 and Accella™ beds

Connex® Vital Signs& Spot Vital Signs®


Ensuring Business Continuity

10

Implementing Comprehensive And Robust Business Continuity Plans

Manufacturing

• Keeping sites and distribution

channels operational

• Increasing capacity of critical products

• Implementing enhanced safety precautions at facilities

• Meeting customer needs with exceptional service capabilities

• Expanding workforce by adding 300+ employees

Supply Chain

• Ensuring uninterrupted supply while minimizing potential disruption

• Partnering with government agencies, upstream suppliers and 3rd party vendors and logistics providers

• Expediting logistics to meet customer needs

• Assessing critical materials and alternative sources

Employees

• Securing health and safety of all Hillrom employees

• Adhering to government, CDC and WHO guidelines

• Facilitating volunteer efforts of employees

• Working with unwavering commitment to support customers, front-line caregivers and patients

11

Q2 2020 Highlights

12


Key Takeaways

✓ Hillrom is playing a pivotal role in global

COVID-19 response

✓ Q2 2020 results demonstrate strength of

underlying business portfolio

✓ Portfolio diversity and financial strength allow

focus on advancing strategic priorities

✓ New product innovation is a key pillar to

driving our competitive advantage and

growth strategy

✓ Remain confident in our long-term growth

prospects and adding value to the delivery

of health care

12

Patient

Support

SystemsFront

Line Care

Surgical

Solutions

$2.9BFY 2019

Transforming to drive sustainable profitable growth and shareholder value

InnovationLeadership

2019 Revenue by BusinessUS$ Billions

New Product RevenueUS$ Millions

Key Valuation MetricsAs of 3/31/2020

FY 2018 FY 2019 FY 2020

Outlook

$300M+

Value

$450M+

$550M+


Global medical technology leader with a diversified portfolio

Advancing category leadership with healthcare solutions

Market

Capitalization

Enterprise

Value

Fiscal YTD 2020

Returned to

Shareholders2

$6.7B $8.6B

$99M-4%LTM Total

Shareholder

Return1

Hillrom: Trusted Medical Technology Innovator

13

Note: Hillrom’s fiscal year end is September 30; 1Includes dividends; 2Includes dividends and share repurchases

Driving operational execution and strong financial performance

• Delivering +6% core revenue* growth, the 8th consecutive quarter of mid-single digit growth

• Exceeding adjusted EPS guidance range of $1.14 to $1.16 with adjusted EPS of $1.28 (+12%)

Expanding internationally and penetrating emerging markets

• Improving performance as COVID-19 demand offsets impact from timing of large capital projects

• Delivering double-digit growth in Canada, Latin America and Asia Pacific (including China)

Transforming the portfolio with select M&A and optimization initiatives

• Partnering with AglieMD to provide up-to-date COVID-19 clinical pathways to caregiver workflows

• Completing Excel Medical acquisition to improve clinical workflows and real-time waveforms

Advancing category leadership with differentiated solutions and innovation

• Introducing a spectrum of new product innovations to meet treatment challenges of COVID-19

• Doubling production of critical care products and 5-fold increase of Life2000 NIV ventilators

Note: Adjusted gross margin, operating margin and EPS are non-GAAP measures. See reconciliation to reported GAAP numbers in the

appendix to this presentation; NIV = non-invasive; *Core revenue excludes foreign currency, divestitures and non-strategic assets the

company may exit, including Surgical Solutions international OEM business © 2020 Hill-Rom Services, Inc. ALL RIGHTS RESERVED.

Enhancing Shareholder Value By Executing Our Strategy

Hillrom: Strategic Priorities

14

For “Sustainable

Procurement”


Promoting Excellence In The Workplace

15

Dave Thomas Foundation

Award Recognizes

Adoption Benefits

American Heart

Association Workplace

Health Achievement

Award

(Gold Level)

Silver Cradle Award

Recognizes

Adoption Benefits

Great Place to Work

Award2

1Awarded in Mexico; 2Awarded in France

Diversity & Inclusion

Award1

Newsweek’s

America’s Most

Responsible

Companies

The Corporate Board

Initiative Acknowledges

the Advancement of

Women on Boards

For Gender Diversity

on Hillrom’s Board of

Directors

For “Sustainable

Procurement”

Diversity & Inclusion

Award1

16

Q2 2020 Financial Summary

YTD 2019 YTD 2020

OperatingCash Flow

Q2 2019 Q2 2020

Global Revenue


17

Delivering Strong Q2 Core Revenue And Adjusted EPS Growth

Q2 2019 Q2 2020

Adj. Earnings Per Diluted Share

$714M$1.14

$1.28 $157M$158M$723M

+6%Core*

GrowthGrowth

flatGrowth


appendix to this presentation; *Core revenue excludes foreign currency, divestitures and non-strategic assets the company may exit,

including Surgical Solutions international OEM business

+19%Ex. Divestiture

+12%Reported

Q2 2020 Financial Results

Fiscal Second Quarter

Adjusted P&L 2019 2020YOY

Change

Revenue $714M $723M

Gross Margin 49.4% 51.2% +180 bps

Operating Margin 16.4% 18.3% +190 bps

Adjusted EPS $1.14 $1.28 +12%

+2%constant currency


Q2 2020 Financial Results

Achieving Strong Q2 Performance And Exceeding Adjusted EPS Guidance With Double-Digit Growth


appendix to this presentation; *Core revenue excludes foreign currency, divestitures and non-strategic assets the company may exit,

including Surgical Solutions international OEM business

18

+6%core*

growth


Driving Durable, Sustainable Mid-Single Digit Top-Line Growth For 8 Consecutive Quarters

Core Revenue* Growth

*Core revenue excludes foreign currency, divestitures and non-strategic assets the company may exit, including Surgical Solutions

international OEM business

19

Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020

6%

4%

8%

6%

100+

bps

150+

bps

Core Growth Impact of Acquisitions

2%

6%

2%

4%

6%

~200

bps

6%

~200

bps

Delivering double-digit growth of smart bed systems

Driving improved international performance with strong ICU bed demand

Launching new products including Voalte Extend

Partnering with AgileMDto provide digital COVID-19 clinical pathways

Driving strong U.S. growth across surgical equipment

Achieving double-digit growth of Integrated Table Motion

Offsetting U.S. growth with impact from timing of large international capital projects

Exiting lower margin non-core revenue

Achieving high single-digit growth rate in 1H 2020

Accelerating growth of vital signs and thermometry

Ramping key products including 5x increase of Life2000 NIV ventilators

Launching new Spot Vital Signs 4400 device in U.S. and Canada

Patient Support Systems Surgical SolutionsFront Line Care

Q2 2020 Q2 2020 Q2 2020


Q2 2020 Revenue By Business

Note: All revenue growth rates are constant currency; OUS = outside the United States; *Core revenue excludes foreign currency,

divestitures and non-strategic assets the company may exit, including Surgical Solutions international OEM business

20

+180 bpsGross Margin Expansion

Adjusted Gross Margin

Q2 2019 GM

Expansion

Operating

Expenses

Q2 2020Q2 2019 Product

Mix

Operational

Improvements*

Q2 2020

Adjusted Operating Margin

+140 bps+180 bps

+190 bpsOperating Margin Expansion

+10 bps+40 bps


Driving Continued Gross Margin Expansion With Positive Product Mix And Operational Improvements

Q2 2020 Margin Expansion

Note: Axis not to scale; Adjusted gross margin, operating margin and EPS are non-GAAP measures. See reconciliation to reported

GAAP numbers in the appendix to this presentation; *Includes tariffs and related impact

49.4%

51.2%

16.4%

18.3%

21

$1.28Adjusted Earnings Per Diluted Share

$1.14

$1.28

Q2 2019 Q2 2020

Adjusted EPS GrowthUS$

+12%growth

• Delivering core revenue* growth of +6% including positive contribution from new products, acquisitions and ~$15M net tailwind from COVID-19 demand

• Expanding margins driven by improved product mix and benefits of manufacturing cost and sourcing efficiencies

• Investing in strategic initiatives including IT transformation and emerging markets to drive future growth

• Absorbing approximately $0.06 dilution related to surgical consumables divestiture


Exceeding Guidance With +12% Adjusted EPS Growth

Q2 2020 Adjusted Earnings Per Diluted Share

Note: Axis not to scale; Adjusted gross margin, operating margin and EPS are non-GAAP measures. See reconciliation to reported

GAAP numbers in the appendix to this presentation; *Core revenue excludes foreign currency, divestitures and non-strategic assets the

company may exit, including Surgical Solutions international OEM business

22


23Note: Leverage ratio calculated as Total Debt, divided by EBITDA. EBITDA is calculated as defined in Hillrom’s

compliance certificate under its existing credit facility; Debt maturity based on calendar year; *Reflecting total gross

revolving credit, not reflecting drawdowns

✓ Deploying disciplined approach to M&A

✓ Reducing debt levels; no significant

debt maturity until 2024

✓ Raising quarterly dividend for 10th

consecutive year

✓ Offsetting stock option dilution with

share buy backs

✓ Operating well within debt and interest

leverage covenants

$291MCash And

Cash Equivalents

$1.2BTotal Revolving

Credit*

3.3xDebt-to-EBITDA

Leverage

Balancing Capital Allocation:

Preserving Financial Flexibility To Continue To Invest In Our Strategic Priorities

Maintaining Strong Balance Sheet And Liquidity


24

Voalte Breathe Technologies Excel Medical

• Advancing our Advancing Connected Care vision

• Providing real-time insights at point of care

• Integrating Voalte into our digital offering and Care Communications business

• Leveraging strong Hillrom acute care relationships

• Utilizing smart phone platform to enhance clinical workflows

• Addressing growing market needs

• Shifting care closer to home with a

mobile solution

• Strengthening our Respiratory

Health portfolio

• Leveraging existing customer base

and business model

• Adopting NIV therapy drives 91%

compliance within 1 year of

adoption1; may reduce ER visits by

68% and total costs by 79%2

• Expanding our digital health capabilities to improve clinical workflow

• Integrating interoperable solutions within Care Communications

• Accelerating ability to integrate with 3rd party devices

• Enabling our Medical Device Integration (MDI) platform

• Expanding capabilities of real-time waveforms in digital format for reference and trending information

Integrating Businesses And Products That Advance Our Strategy

1Breathe: Health care utilization and respiratory status following the addition of a portable non-invasive open ventilator

to the treatment regimen. Presented at CHEST, 2015.. 2Neil R. MacIntyre, MD. Clinical Chief, Pulmonary/Critical Care

Division. Medical Director, Respiratory Care Services. Professor of Medicine. Duke University.

Transforming The Portfolio With Disciplined M&A


25

Fiscal

Q2

Fiscal

Q3

Fiscal

Q4

Preparedness Gradual RecoveryPeak Demand

• Diverse portfolio provides natural hedging

• Record orders and backlog of smart beds exiting Q2 (orders +70% vs. Q1)

• No second wave anticipated in fiscal 2020; long-term outlook for capital purchases is evolving

• No material manufacturing and supply chain operations disruptions

• Expanding capacity remains on track

~60% of RevenueResilient Demand in Near-Term

Specialty beds, vital signs monitors, respiratory care

and other diagnostic tools

~40% of Revenue Reduced Demand in Near-Term

Surgical solutions, care communications, vision care

and other physician-office products

• Anticipate more than 20% decline in fiscal 2H across these categories

• Limited hospital access to complete installations; delays in large capital projects

• Customers considering reduction in non-emergent capital expenditures

• Reduced levels of surgical procedures; fewer physician office visits

Net Impact Depends On Scope, Intensity And Duration Of Pandemic AND Shape Of Recovery In The Demand For Healthcare Globally

Fiscal 2020 Outlook

26

Revenue Schedules

United States International Total United States International Total United States International Total United States International Total

Patient Support Systems 266.6$ 77.6$ 344.2$ 248.1$ 92.9$ 341.0$ 7.5% -16.5% 0.9% 7.5% -14.6% 1.4%

Front Line Care 178.1 76.5 254.6 166.5 66.9 233.4 7.0% 14.3% 9.1% 7.0% 15.1% 9.3%

Surgical Solutions 37.1 49.1 86.2 53.9 55.2 109.1 -31.2% -11.1% -21.0% -31.2% -9.2% -20.0%

Total Hillrom 481.8$ 203.2$ 685.0$ 468.5$ 215.0$ 683.5$ 2.8% -5.5% 0.2% 2.8% -4.0% 0.7%


Patient Support Systems 289.3$ 92.8$ 382.1$ 267.2$ 92.4$ 359.6$ 8.3% 0.4% 6.3% 8.3% 4.1% 7.2%

Front Line Care 179.2 79.0 258.2 170.2 72.9 243.1 5.3% 8.4% 6.2% 5.3% 10.8% 7.0%


Total Hillrom 506.5$ 216.7$ 723.2$ 493.0$ 221.2$ 714.2$ 2.7% -2.0% 1.3% 2.7% 0.9% 2.2%

Q1 2019 % Growth @ Actual Rates % Growth @ Constant Rates

Q2 2019 % Growth @ Actual Rates % Growth @ Constant Rates

Q1 2020

Q2 2020

2020 Revenue Tables

© 2020 Hill-Rom Services, Inc. ALL RIGHTS RESERVED.Note: Totals may not add due to rounding

27



Front Line Care 166.5 66.9 233.4 156.4 66.4 222.8 6.5% 0.8% 4.8% 6.5% 3.3% 5.5%

Surgical Solutions 53.9 55.2 109.1 50.9 59.8 110.7 5.9% -7.7% -1.4% 5.9% -5.0% 0.0%

Total Hill-Rom 468.5$ 215.0$ 683.5$ 449.1$ 216.4$ 665.5$ 4.3% -0.6% 2.7% 4.3% 2.3% 3.7%



Front Line Care 170.2 72.9 243.1 163.1 75.0 238.1 4.4% -2.8% 2.1% 4.4% 2.7% 3.8%

Surgical Solutions 55.6 55.9 111.5 54.4 63.2 117.6 2.2% -11.6% -5.2% 2.2% -5.2% -1.8%

Total Hill-Rom 493.0$ 221.2$ 714.2$ 461.1$ 244.4$ 705.5$ 6.9% -9.5% 1.2% 6.9% -3.6% 3.3%



Front Line Care 178.4 66.0 244.4 170.8 69.5 240.3 4.4% -5.0% 1.7% 4.4% -1.4% 2.7%

Surgical Solutions 60.2 47.7 107.9 55.6 54.3 109.9 8.3% -12.2% -1.8% 8.3% -8.1% 0.2%

Total Hill-Rom 529.4$ 197.4$ 726.8$ 488.5$ 215.0$ 703.5$ 8.4% -8.2% 3.3% 8.4% -4.2% 4.5%



Front Line Care 185.5 71.7 257.2 193.6 69.0 262.6 -4.2% 3.9% -2.1% -4.2% 6.5% -1.4%

Surgical Solutions 51.5 58.7 110.2 60.6 59.5 120.1 -15.0% -1.3% -8.2% -15.0% 2.7% -6.2%

Total Hill-Rom 565.9$ 216.9$ 782.8$ 544.2$ 215.0$ 759.2$ 4.0% 0.9% 3.1% 4.0% 4.4% 4.1%


Patient Support Systems 1,135.0$ 355.5$ 1,490.5$ 1,037.6$ 374.1$ 1,411.7$ 9.4% -5.0% 5.6% 9.4% -0.6% 6.7%

Front Line Care 700.6 277.5 978.1 683.8 279.9 963.7 2.5% -0.9% 1.5% 2.5% 2.8% 2.5%


Total Hill-Rom 2,056.8$ 850.5$ 2,907.3$ 1,942.9$ 890.8$ 2,833.7$ 5.9% -4.5% 2.6% 5.9% -0.4% 3.9%

FY 2019 FY 2018 % Growth @ Actual Rates % Growth @ Constant Rates

Q2 2019 Q2 2018 % Growth @ Actual Rates % Growth @ Constant Rates




2019 Revenue Tables

© 2020 Hill-Rom Services, Inc. ALL RIGHTS RESERVED.Note: Totals may not add due to rounding

28

($ in millions) Patient Support Systems Surgical Solutions Total Non-Core

U.S. OUS Total U.S. OUS Total U.S. OUS Total

Q1 2020 $0.0 $0.0 $0.0 $0.0 $9.1 $9.1 $0.0 $9.1 $9.1

Q2 2020 $0.0 $0.1 $0.1 $0.0 $10.8 $10.8 $0.0 $10.9 $10.9

Q1 2019 $2.3 $0.4 $2.7 $21.6 $16.1 $37.6 $23.8 $16.5 $40.3

Q2 2019 $2.2 $0.3 $2.5 $21.0 $15.4 $36.4 $23.2 $15.6 $38.9

Q3 2019 $8.0 $0.0 $8.0 $23.3 $14.2 $37.4 $31.3 $14.2 $45.5

Q4 2019 $0.4 $0.0 $0.4 $8.4 $14.0 $22.4 $8.7 $14.0 $22.7

Fiscal 2019 $12.9 $0.7 $13.5 $74.2 $59.6 $133.8 $87.1 $60.2 $147.3

© 2020 Hill-Rom Services, Inc. ALL RIGHTS RESERVED.Note: Non-core revenue includes divestitures and non-strategic assets the company may exit, including Surgical Solutions international

OEM business; Totals may not add due to rounding

29

2020 & 2019 Non-Core Revenue Including Surgical Consumables


Divesting $300M+ Of Annualized Revenue Over Last 5 Years

Winding Down Non-Core Revenue* In 2020

*Core revenue excludes foreign currency, divestitures and non-strategic assets the company may exit, including Surgical Solutions

international OEM business

30

FY 2018 FY 2019 FY 2020

Outlook

FY 2021

Outlook

FY 2022

Outlook

~$210M

~$150M

~$40M

~$0M ~$0M

31

Appendix:Reconciliation Of Non-GAAP Disclosures

Reconciliation: Operating Margin And Earnings Per Diluted Share


32

Operating

Margin

Income

Before

Income Taxes

Income Tax

Expense Diluted EPS

Operating

Margin

Income

Before

Income Taxes

Income Tax

Expense Diluted EPS

GAAP Basis 12.1% 56.8$ 9.9$ 0.70$ 11.4% 60.7$ 11.2$ 0.74$

Adjustments:

Acquisition and integration costs and related fair value

adjustments 0.4% 2.7 0.7 0.03 0.2% 1.6 0.3 0.02

Acquisition-related intangible asset amortization 3.7% 27.1 6.6 0.31 3.8% 27.3 6.4 0.30

Field corrective actions 0.2% 1.4 0.4 0.01 - - - -

Regulatory compliance costs 0.7% 4.8 1.2 0.05 0.5% 3.3 0.9 0.04

Special charges 1.2% 8.8 2.3 0.10 0.5% 3.5 0.9 0.04

Pension Settlement Expense 0.0% 8.5 2.0 0.09 - - - -

Litigation Settlement 0.0% (1.2) (0.3) (0.01) - - - -

Adjusted Basis 18.3% 108.9$ 22.8$ 1.28$ 16.4% 96.4$ 19.7$ 1.14$

Operating

Margin

Income

Before

Income Taxes

Income Tax

Expense Diluted EPS

Operating

Margin

Income

Before

Income Taxes

Income Tax

Expense Diluted EPS

GAAP Basis 11.8% 99.4$ 12.7$ 1.29$ 10.9% 110.3$ 18.6$ 1.36$

Adjustments:

Acquisition and integration costs and related fair value

adjustments -0.3% (3.8) 1.0 (0.07) 0.1% 1.8 0.4 0.02

Acquisition-related intangible asset amortization 3.8% 53.8 13.0 0.61 3.8% 53.0 12.3 0.60

Field corrective actions 0.1% 1.4 0.4 0.01 - - - -

Regulatory compliance costs 0.6% 8.7 1.8 0.10 0.5% 6.1 1.6 0.07

Special charges 1.2% 16.6 3.5 0.19 0.8% 11.5 2.8 0.13

Tax law and method changes 0.0% - - - - - 1.0 (0.02)

Debt refinancing costs 0.0% 16.1 3.7 0.18 - - - -

(Gain) Loss on disposition 0.0% 0.4 0.1 0.01 - - - -

Pension Settlement Expense 0.0% 8.5 2.0 0.10 - - - -

Litigation Settlement 0.0% (1.2) (0.3) (0.01) - - - -

Adjusted Basis 17.2% 199.9$ 37.9$ 2.41$ 16.1% 182.7$ 36.7$ 2.16

Quarter Ended March 31, 2019

Year to Date Ended March 31, 2019

Quarter Ended March 31, 2020

Year to Date Ended March 31, 2020

advancing connected caretm · logistics providers •expediting logistics to meet customer needs...

Documents